# US 2023/0398198 A1 · STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398198 A1
- Document ID: US20230398198A1
- Status: Published application
- Kind: A1
- Application number: 18/234,742
- Filed: 2023-08-16
- Published: 2023-12-14
- Earliest claimed: 2011-08-04
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Victor Nizet; Nina van Sorge
- Web page: https://patentgrep.com/patent/US20230398198A1

## CPC

- A61K 39/092: {Streptococcus}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C07K 16/1275: Streptococcus (G)
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C08B 37/0006: {Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid}
- C12N 1/36: Adaptation or attenuation of cells
- G01N 33/56938: {Staphylococcus}
- G01N 33/56944: {Streptococcus}
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- G01N 2400/02: involving antibodies to sugar part of glycoproteins
- G01N 2500/00: Screening for compounds of potential therapeutic value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.

## Claims

### Claim 1

An immunogenic composition comprising a Group A Streptococcus (GAS) carbohydrate or glycoconjugate having a polyrhamnose backbone and which completely lacks an N-acetyl-D-glucosamine (GlcNac) side chain.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, further comprising an adjuvant.

### Claim 3 (depends on 2)

The immunogenic composition of claim 2, wherein the adjuvant is selected from the group consisting of Freund's adjuvant, alum, aluminum phosphate, aluminum hydroxide, squalene, complete Freund's adjuvant, and levamisole.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, further comprising a pharmaceutical carrier.

### Claim 5 (depends on 4)

The immunogenic composition of claim 4, wherein the pharmaceutical carrier is a liposome.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1 comprising a glycoconjugate, wherein the polyrhamnose is conjugated to a protein.

### Claim 7 (depends on 6)

The immunogenic composition of claim 6, wherein the protein is a GAS protein.

### Claim 8 (depends on 6)

The immunogenic composition of claim 6, wherein the protein is not a GAS protein.

### Claim 9

A composition comprising an antigen consisting of purified Group A Streptococcus (GAS) carbohydrates or glycoconjugates having a polyrhamnose backbone and which completely lack an N-acetyl-D-glucosamine (GlcNac) side chain.

### Claim 10 (depends on 9)

The composition of claim 9, further comprising an adjuvant.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the adjuvant is selected from the group consisting of Freund's adjuvant, alum, aluminum phosphate, aluminum hydroxide, squalene, complete Freund's adjuvant, and levamisole.

### Claim 12 (depends on 9)

The composition of claim 9, further comprising a pharmaceutically acceptable carrier.

### Claim 13 (depends on 9)

The composition of claim 9, wherein the composition is a liposomal composition.

### Claim 14 (depends on 9)

The composition of claim 9, wherein the antigen consists of glycoconjugates, wherein the polyrhamnose is conjugated to a protein.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the protein is a GAS protein.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the protein is not a GAS protein.
